[PI3K and mTOR pathway and molecular targeted agents]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• PI3K and mTOR pathway molecular alterations are prevalent in diverse cancers.
• PIK3CA mutations serve as predictive biomarkers for anti-EGFR antibodies, trastuzumab, and lapatinib efficacy.
• Development of p110 isoform-selective PI3K inhibitors aims to minimize off-target adverse events.

Purpose of the Study:

• To investigate the role of PI3K/mTOR pathway alterations in cancer.
• To evaluate the efficacy of novel PI3K inhibitors in overcoming resistance mechanisms.
• To explore strategies for reducing adverse events associated with PI3K pathway inhibition.

Main Methods:

• Analysis of molecular alterations in PI3K and mTOR pathways.
• Evaluation of PIK3CA mutation status as a predictive marker.
• Assessment of isoform-selective PI3K inhibitors in preclinical or clinical models.
• Investigation of feedback loops contributing to resistance against PI3K inhibitors.

Main Results:

• Frequent molecular alterations observed in PI3K and mTOR pathways across various cancer types.
• PIK3CA mutations identified as key predictors for response to specific targeted therapies.
• Development of isoform-selective PI3K inhibitors shows potential for reduced toxicity.
• Feedback mechanisms identified as a significant cause of resistance to PI3K inhibitors.

Conclusions:

• Targeting PI3K and mTOR pathways remains a critical strategy in cancer therapy.
• Isoform-selective and mutation-selective inhibitors are promising approaches to enhance efficacy and tolerability.
• Understanding and overcoming resistance mechanisms, such as feedback loops, is essential for successful treatment outcomes.